GlaxoSmithKline Plc has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the U.K.-based giant is struggling.
Source: Tiny U.K. Biotech Takes On Glaxo’s $730,000 Gene Therapy